142 related articles for article (PubMed ID: 10327032)
21. Symptomatic cardiotoxicity associated with 5-fluorouracil.
Meyer CC; Calis KA; Burke LB; Walawander CA; Grasela TH
Pharmacotherapy; 1997; 17(4):729-36. PubMed ID: 9250550
[TBL] [Abstract][Full Text] [Related]
22. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
Garufi C; Lévi F; Aschelter AM; Pace R; Giunta S; Nisticò C; Gallà DA; Silecchia GF; Franchi F; Narduzzi C; Terzoli E
Eur J Cancer; 1997 Sep; 33(10):1566-71. PubMed ID: 9389916
[TBL] [Abstract][Full Text] [Related]
24. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Glimelius B; Jakobsen A; Graf W; Berglund A; Gadeberg C; Hansen P; Kjaer M; Brunsgaard N; Sandberg E; Lindberg B; Sellström H; Lorentz T; Påhlman L; Gustavsson B
Eur J Cancer; 1998 Apr; 34(5):674-8. PubMed ID: 9713273
[TBL] [Abstract][Full Text] [Related]
25. [A case of hyperammonemic encephalopathy related to 5-FU in an aged patient with recurrent colon cancer treated with FOLFIRI therapy].
Okamura T; Kawachi Y; Nikkuni K; Nishimura A; Makino S; Kawahara M; Kitami C; Hashimoto Y
Gan To Kagaku Ryoho; 2013 May; 40(5):671-3. PubMed ID: 23863598
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study.
Berenberg JL; Tangen C; Macdonald JS; Hutchins LF; Natale RB; Oishi N; Guy JT; Fleming TR
Cancer; 1995 Sep; 76(5):715-9. PubMed ID: 8625171
[TBL] [Abstract][Full Text] [Related]
27. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Chiara S; Nobile MT; Barzacchi C; Sanguineti O; Vincenti M; Di Somma C; Meszaros P; Rosso R
Eur J Cancer; 1997 May; 33(6):967-9. PubMed ID: 9291822
[TBL] [Abstract][Full Text] [Related]
28. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
Arkenau HT; Rettig K; Porschen R
Int J Colorectal Dis; 2005 May; 20(3):258-61. PubMed ID: 15549327
[TBL] [Abstract][Full Text] [Related]
30. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
[TBL] [Abstract][Full Text] [Related]
31. A case of acute myocardial infarction during 5-fluorouracil infusion.
Canale ML; Camerini A; Stroppa S; Porta RP; Caravelli P; Mariani M; Balbarini A; Ricci S
J Cardiovasc Med (Hagerstown); 2006 Nov; 7(11):835-7. PubMed ID: 17060812
[TBL] [Abstract][Full Text] [Related]
32. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Streit M; Jaehde U; Stremetzne S; Ridwelski K; Kerz H; Strohbach F; Hohenberger P; Zwiebel FM; Hebart H; Böthig R; Kairies M; Zillig D; Schuchmann S; Warnecke S; Thiel E; Kreuser ED
Ann Oncol; 1997 Nov; 8(11):163-5. PubMed ID: 9426339
[TBL] [Abstract][Full Text] [Related]
33. Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Chu L; Sutton LM; Peterson BL; Havlin KA; Winer EP
J Infus Chemother; 1996; 6(4):211-6. PubMed ID: 9229318
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
35. 5-Fluorouracil Infiltrations and Ambulatory Pumps: Education, Prevention, and Management Considerations.
Bostelman C
Clin J Oncol Nurs; 2019 Oct; 23(5):537-539. PubMed ID: 31538980
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer.
Thrall MM; Wood P; King V; Rivera W; Hrushesky W
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):873-81. PubMed ID: 10705008
[TBL] [Abstract][Full Text] [Related]
37. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
[TBL] [Abstract][Full Text] [Related]
38. [Hyperammonemic encephalopathy after treatment with modified FOLFOX6 regimen for recurrent gastric cancer:a case report].
Kuwabara S; Murakawa K; Kumagai K; Takeuchi Y; Wada H; Ichinokawa M; Matsumoto J; Ono K; Hirano S
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(1):72-78. PubMed ID: 35022374
[TBL] [Abstract][Full Text] [Related]
39. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
